{"output": [["Axovant Sciences Ltd", "COMP", "Scrap", "Lead Experimental Dementia Treatment", "PRODUCT"], ["Axovant Sciences Ltd", "COMP", "Fail", "Mid-Stage Study", "EVENT"], ["Axovant Sciences Ltd", "COMP", "Stop", "Development of Drug", "PRODUCT"], ["Axovant Sciences Ltd", "COMP", "Operate_In", "Neurological Disorders Sector", "SECTOR"], ["Pfizer Inc", "COMP", "Abandon", "Research to Find New Drugs", "PRODUCT"], ["Intepirdine", "PRODUCT", "Not_Effective", "Improving Motor Function", "CONCEPT"], ["David Hung", "PERSON", "Say", "No_Evidence_to_Support_Further_Development", "CONCEPT"], ["Nelotanserin", "PRODUCT", "Positive_Trends_in_Efficacy", "Some Patients with LBD and Parkinson\u2019s disease dementia", "PERSON"], ["Axovant Sciences Ltd", "COMP", "Advance_Development", "Nelotanserin", "PRODUCT"], ["Axovant Sciences Ltd", "COMP", "Conduct", "Late-Stage Study", "EVENT"], ["Axovant Sciences Ltd", "COMP", "Discuss", "U.S. Regulator", "ORG/REG"], ["Leerink analyst Joseph Schwartz", "PERSON", "Not_Convince", "Investors about Drug\u2019s Prospects", "CONCEPT"], ["Axovant Sciences Ltd", "COMP", "Share_Falls", "49.7%", "ECON_INDICATOR"], ["Axovant Sciences Ltd", "COMP", "Share_Falls", "78%", "ECON_INDICATOR"], ["Intepirdine", "PRODUCT", "Fail", "Alzheimer\u2019s Trial", "EVENT"]], "published": "2018-01-08T14:51:00.000+02:00"}